Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

An amendment to this paper has been published and can be accessed via the original article.

Bibliographic Details
Main Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Arthritis Research & Therapy
Online Access:http://link.springer.com/article/10.1186/s13075-020-02247-3
id doaj-89af8f427d574a628004b16ceffc0493
record_format Article
spelling doaj-89af8f427d574a628004b16ceffc04932020-11-25T03:28:15ZengBMCArthritis Research & Therapy1478-63622020-06-012211210.1186/s13075-020-02247-3Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanTsutomu Takeuchi0Yoshiya Tanaka1Sakae Tanaka2Atsushi Kawakami3Yeong-Wook Song4Yi-Hsing Chen5Mitsuhiro Rokuda6Hiroyuki Izutsu7Satoshi Ushijima8Yuichiro Kaneko9Yoshihiro Nakashima10Teruaki Shiomi11Emi Yamada12Keio University School of MedicineUniversity of Occupational and Environmental Health, JapanUniversity of TokyoNagasaki University Graduate School of Biomedical SciencesSeoul National University, Seoul National University HospitalTaichung Veterans General HospitalAstellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.Astellas Pharma, Inc.An amendment to this paper has been published and can be accessed via the original article.http://link.springer.com/article/10.1186/s13075-020-02247-3
collection DOAJ
language English
format Article
sources DOAJ
author Tsutomu Takeuchi
Yoshiya Tanaka
Sakae Tanaka
Atsushi Kawakami
Yeong-Wook Song
Yi-Hsing Chen
Mitsuhiro Rokuda
Hiroyuki Izutsu
Satoshi Ushijima
Yuichiro Kaneko
Yoshihiro Nakashima
Teruaki Shiomi
Emi Yamada
spellingShingle Tsutomu Takeuchi
Yoshiya Tanaka
Sakae Tanaka
Atsushi Kawakami
Yeong-Wook Song
Yi-Hsing Chen
Mitsuhiro Rokuda
Hiroyuki Izutsu
Satoshi Ushijima
Yuichiro Kaneko
Yoshihiro Nakashima
Teruaki Shiomi
Emi Yamada
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
Arthritis Research & Therapy
author_facet Tsutomu Takeuchi
Yoshiya Tanaka
Sakae Tanaka
Atsushi Kawakami
Yeong-Wook Song
Yi-Hsing Chen
Mitsuhiro Rokuda
Hiroyuki Izutsu
Satoshi Ushijima
Yuichiro Kaneko
Yoshihiro Nakashima
Teruaki Shiomi
Emi Yamada
author_sort Tsutomu Takeuchi
title Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
title_short Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
title_full Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
title_fullStr Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
title_full_unstemmed Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
title_sort correction to: safety and effectiveness of peficitinib (asp015k) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in japan, korea, and taiwan
publisher BMC
series Arthritis Research & Therapy
issn 1478-6362
publishDate 2020-06-01
description An amendment to this paper has been published and can be accessed via the original article.
url http://link.springer.com/article/10.1186/s13075-020-02247-3
work_keys_str_mv AT tsutomutakeuchi correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT yoshiyatanaka correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT sakaetanaka correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT atsushikawakami correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT yeongwooksong correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT yihsingchen correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT mitsuhirorokuda correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT hiroyukiizutsu correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT satoshiushijima correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT yuichirokaneko correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT yoshihironakashima correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT teruakishiomi correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
AT emiyamada correctiontosafetyandeffectivenessofpeficitinibasp015kinpatientswithrheumatoidarthritisinterimdata227monthsmeanpeficitinibtreatmentfromalongtermopenlabelextensionstudyinjapankoreaandtaiwan
_version_ 1724585468230631424

Similar Items